CD8A and cancer: Neoantigen targeted cancer vaccines can activateand expand the antitumor T cell repertoire, but historically, clinicalresponses have been poor because immunity against peptide antigensis typically weak, resulting in insufficient activation of CD8+ cytotoxic T cells.